SCHEMBL23311353

SCHEMBL23311353

CCCCCC(CCCCC)CN1CCN(C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
GNAI3 P08754 2/20 0.38
GNAO1 P09471 2/20 0.38
GNAI1 P63096 2/20 0.38
OPRM1 P35372 2/20 0.38
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
DRD3 P35462 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
CYP2D6 P10635 1/20 0.38
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18613801 0.98 LMNA (0.42) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL18615532 0.98 LMNA (0.42) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL20793891 0.98 LMNA (0.42) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL19523118 0.98 LMNA (0.42) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL19153729 0.96 LMNA (0.41) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL21015468 0.94 CHRM2 (0.42) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL28799501 0.89 LMNA (0.34) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL20214875 0.86 CHRM2 (0.51) GNAI3GNAO1GNAI1OPRM1CHRM2
SCHEMBL18814677 0.85 CHRM2 (0.41) LMNAGNAI3GNAO1GNAI1OPRM1
SCHEMBL25654336 0.85 GNAO1 (0.52) LMNAGNAI3GNAO1GNAI1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11684615-B2 Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-27 US disclosed
US-20210121448-A1 METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2021-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210121448-A1 METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS WNT3, CTNNB1, WNT3A LMNA 731/4885GNAI3 498/4885GNAO1 710/4885
US-11684615-B2 Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors WNT3, WNT3A, WNT1 LMNA 1044/4885GNAI3 510/4885GNAO1 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.